JCR Pharmaceuticals Co., Ltd.

4552

JP3701000006

Pharmaceuticals

Delayed Japan Exchange Other stock markets 01:05:20 2024-05-29 am EDT			5-day change	1st Jan Change
539 ^JPY	-1.82%		-8.02%	-54.01%

May. 27	Jefferies Adjusts JCR Pharmaceuticals’ Price Target to 560 Yen From 1,200 Yen, Keeps at Hold	MT
May. 10	JCR Pharmaceuticals Co., Ltd. Announces Dividend for the Year Ended March 31, 2024, Payable on June 27, 2024	CI

JCR Pharmaceuticals Co., Ltd. Appoints Yoshiaki Ijiri as Executive Fellow and Director, Human Resources Planning Dept

October 03, 2022 at 03:00 am EDT

JCR Pharmaceuticals Co., Ltd. announced appointment of Yoshiaki Ijiri as Executive Fellow and Director, Human Resources Planning Dept. effective from October 1, 2022.

Latest news about JCR Pharmaceuticals Co., Ltd.

Jefferies Adjusts JCR Pharmaceuticals’ Price Target to 560 Yen From 1,200 Yen, Keeps at Hold	May. 27	MT
JCR Pharmaceuticals Co., Ltd. Announces Dividend for the Year Ended March 31, 2024, Payable on June 27, 2024	May. 10	CI
JCR Pharmaceuticals Co., Ltd. Announces Management Changes, Effective as of June 26, 2024	Apr. 25	CI
US Fed Rate Outlook Catapults Japanese Shares to Fresh 52-Week Peak	Mar. 21	MT
JCR Pharmaceuticals Achieves Neurodegenerative Treatment Research Milestone With Alexion	Mar. 20	MT
JCR Pharmaceuticals Co., Ltd. Announces Achievement of Milestone Using J-Brain Cargo Technology for Neurodegenerative Disease in Research Collaboration with Alexion	Mar. 19	CI
JCR Pharmaceuticals Co., Ltd.(TSE:4552) dropped from FTSE All-World Index	Mar. 17	CI
Mycenax Biotech Inc. announced that it expects to receive funding from Center Laboratories, Inc., JCR Pharmaceuticals Co., Ltd., Taiwan BioVenture Company, Jason Technologies Ltd	Mar. 12	CI
JCR Pharmaceuticals Co., Ltd. Announces Organizational and Personnel Changes	Feb. 28	CI
JCR Pharmaceuticals Co., Ltd. Presents Clinical Data on J-Brain Cargo®? to Deliver Medicines Across the Blood-Brain Barrier	Feb. 14	CI
JCR Pharmaceuticals Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	Feb. 08	CI
Asia Markets Remain Mixed as Investors Step Back Following Rally	Dec. 21	MT
Japanese Shares Slip Back into Red as Wall Street Ends Winning Streak Ahead of Key US Data	Dec. 21	MT
JCR Pharmaceuticals' Partner Takeda to Scrap Gene Therapy Collaboration	Dec. 21	MT
JCR Pharmaceuticals Co., Ltd. and Takeda Pharmaceutical Co., Ltd. Announces Discontinuation of Gene Therapy Collaboration	Dec. 20	CI
JCR Announces Research Collaboration, Option and License Agreement with Alexion on Discovery of Oligonucleotide Therapeutics Using J-Brain Cargo	Dec. 20	CI
JCR Pharmaceuticals' Metabolic Disease Drug Candidate Granted FDA's Orphan Drug Designation	Dec. 14	MT
Modalis Therapeutics, JCR Pharmaceuticals Form Drug Delivery Research Partnership	Dec. 12	MT
Modalis Therapeutics Corporation and JCR Pharmaceuticals Enter into Joint Research Agreement	Dec. 12	CI
Japanese Shares Rebound on Wednesday, Boosted by Automotive Stocks	Nov. 22	MT
JCR Pharmaceuticals' Fiscal H1 Attributable Profit Climbs on Increased Drug Sales	Nov. 21	MT
JCR Pharmaceuticals Co., Ltd. Announces First Patient Dosed in a Global Phase I/II Clinical Trial of JR-441 for the Treatment of MPS IIIA	23-10-26	CI
Jefferies Adjusts JCR Pharmaceuticals’ Price Target to 1,200 Yen From 1,400 Yen, Keeps at Hold	23-10-26	MT
JCR Pharmaceuticals Co., Ltd. Declares Interim Dividend for the Fiscal Year Ending March 31, 2024, Payable on December 8, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	23-10-25	CI
Jefferies Adjusts JCR Pharmaceuticals’ Price Target to 1,400 Yen From 1,360 Yen, Keeps at Hold	23-10-05	MT

Chart JCR Pharmaceuticals Co., Ltd.

Duration

Period

More charts

JCR Pharmaceuticals Co., Ltd. is a Japan-based company primarily engaged in the pharmaceutical business, as well as the medical and research equipment business. The Company operates in two segments. The Pharmaceutical segment engages in the research, production, purchase and sale of medical drugs and pharmaceutical raw materials. The Medical and Research Equipment segment engages in the purchase and sale of the medical and research equipment.

Sector

Pharmaceuticals

Calendar

2024-07-24 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for JCR Pharmaceuticals Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

549 JPY

Average target price

1,223 JPY

Spread / Average Target

+122.74%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JCR PHARMACEUTICALS CO., LTD.	-54.01%	437M
ELI LILLY AND COMPANY	+38.59%	727B
JOHNSON & JOHNSON	-7.89%	347B
MERCK & CO., INC.	+15.66%	319B
ABBVIE INC.	+0.24%	274B
ASTRAZENECA PLC	+13.47%	238B
NOVARTIS AG	+7.35%	204B
ROCHE HOLDING AG	-6.42%	203B
AMGEN INC.	+4.23%	161B
PFIZER, INC.	-1.70%	160B

Other Pharmaceuticals